TF1's monthly disclosure includes total shares and voting rights as of September 30, 2025, in compliance with AMF regulations ...

The Platform Group AG raises its 2026 forecast to EUR 1 billion in sales and EUR 70–80 million in EBITDA due to acquisitions in pharmaceutical sector and Optics & Hearing expansion ...

American Critical Minerals Corp. announces successful outcomes at annual meeting. Shareholders re-elected board, approved auditor appointment, and ratified equity plan ...

Notification of manager’s transaction related to Ørsted A/S received under EU Regulation no. 596/2014. Executive Vice President and CFO Trond Westlie's transaction disclosed ...

China Media Group invites the world to the CMG 2025 Mid-Autumn Festival Gala in Deyang, Sichuan Province, showcasing a blend ...

Kaufman & Broad SA reports positive results for the first nine months of 2025 with good commercial activity, strong financial structure, and maintained outlook. Revenue and net orders show significant ...

Investis strengthens financial position by selling 73% stake in PHM Group TopCo Oy for CHF 47 million, resulting in CHF 11 million gain. Equity base reinforced and leverage ratio reduced ...

Saint-Gobain enters exclusive negotiations for the sale of SFIC Belgium, a specialist construction materials distribution business, part of portfolio optimization strategy ...

Rieter Holding Ltd. announces the result of its capital increase through a rights issue. Ad-hoc announcement pursuant to Art. 53 LR ...

Crypto Blockchain Industries SA announces amendment to liquidity contract with TSAF, returning €40,000 in cash and details the resources in the liquidity account as of September 29, 2025 ...

Capital B finalizes capital increase at \u20ac1.70 per share, acquiring 12 BTC for \u20ac1.2 million. BTC holding of 2,812 valued at \u20ac262.1 million. Achieved BTC Yield of 1,656.1% YTD. The compan ...

Genmab to acquire HBM portfolio company Merus for USD 8 billion in cash. Merus is known for its innovative oncology therapies. The transaction with Genmab represents a 41% premium on the closing price ...